Johnson & Johnson (NYSE:JNJ) Shares Sold by Rational Advisors LLC

Rational Advisors LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 39.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,022 shares of the company’s stock after selling 1,305 shares during the quarter. Rational Advisors LLC’s holdings in Johnson & Johnson were worth $328,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Hazlett Burt & Watson Inc. boosted its holdings in Johnson & Johnson by 7.3% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 19,040 shares of the company’s stock valued at $3,082,000 after purchasing an additional 1,298 shares during the last quarter. Quintet Private Bank Europe S.A. raised its stake in shares of Johnson & Johnson by 15.4% in the 3rd quarter. Quintet Private Bank Europe S.A. now owns 42,127 shares of the company’s stock valued at $6,827,000 after acquiring an additional 5,606 shares during the period. PDS Planning Inc raised its stake in shares of Johnson & Johnson by 5.2% in the 3rd quarter. PDS Planning Inc now owns 14,842 shares of the company’s stock valued at $2,405,000 after acquiring an additional 729 shares during the period. QRG Capital Management Inc. increased its stake in Johnson & Johnson by 5.9% during the 3rd quarter. QRG Capital Management Inc. now owns 494,125 shares of the company’s stock worth $80,078,000 after buying an additional 27,484 shares during the period. Finally, Asset Management One Co. Ltd. increased its stake in Johnson & Johnson by 0.8% during the 3rd quarter. Asset Management One Co. Ltd. now owns 1,154,982 shares of the company’s stock worth $187,176,000 after buying an additional 9,585 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.16% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on JNJ. TD Securities lowered their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. The Goldman Sachs Group decreased their price target on shares of Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Morgan Stanley increased their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Daiwa America downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Finally, Royal Bank of Canada upped their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Six equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $175.93.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $158.24 on Tuesday. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The company has a market capitalization of $380.98 billion, a P/E ratio of 22.90, a price-to-earnings-growth ratio of 2.84 and a beta of 0.53. The firm has a 50-day moving average price of $163.18 and a two-hundred day moving average price of $155.68. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The company had revenue of $22.47 billion for the quarter, compared to analysts’ expectations of $22.17 billion. During the same period last year, the company earned $2.66 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. As a group, research analysts expect that Johnson & Johnson will post 9.94 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.13%. Johnson & Johnson’s dividend payout ratio is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.